Related by context. All words. (Click for frequent words.) 80 advanced adenoma 76 atypical hyperplasia 75 colorectal polyp 75 adenomatous polyps 75 colorectal neoplasms 74 adenomas 74 locoregional recurrence 74 renal cell carcinomas 74 colorectal adenoma 73 CIN2 + 73 BRCA1 mutation carriers 73 pCR 73 hormone receptor negative 73 invasive ductal 73 adenoma 73 advanced neoplasia 73 undergone radical prostatectomy 72 contralateral breast 72 HGPIN 72 malignant polyps 72 pT3 72 invasive carcinomas 72 SUVmax 72 preoperative chemotherapy 72 adenocarcinomas 71 distant metastases 71 CIN3 71 colorectal neoplasia 71 pre cancerous polyps 71 HER2 expression 71 neoplasias 71 lobular carcinoma 71 nondiabetic patients 71 nonmelanoma skin cancers 71 underwent surgical resection 71 malignant lesions 71 ductal cancer 71 lymph node involvement 71 TT genotype 71 intravenous bisphosphonates 71 osteosarcomas 71 PSADT 71 specific antigen PSA 71 endometrial hyperplasia 71 axillary lymph nodes 71 bladder cancers 71 lymph node metastases 70 serum PSA 70 lung nodules 70 invasive lobular 70 SLNB 70 polyp recurrence 70 PCa 70 HER2 positive tumors 70 benign breast 70 lobular cancer 70 #.#ng/ml 70 coronary calcification 70 sleeve lobectomy 70 distant metastasis 70 underwent resection 70 pulmonary metastases 70 biochemical recurrence 70 micrometastases 70 basal cell nevus syndrome 70 precancerous polyp 70 ductal breast cancer 70 prostate cancer CaP 70 adenomatous 70 Adenomas 69 subclinical hyperthyroidism 69 ductal carcinomas 69 colorectal adenomas 69 carotid stenosis 69 medically inoperable 69 differentiated thyroid 69 salpingo oophorectomy 69 colorectal polyps 69 endometrial cancers 69 CIN3 + 69 recurrent VTE 69 EBRT 69 BRCA1 mutations 69 HER2 positive cancers 69 estrogen receptor negative 69 HNSCC 69 epithelial tumors 69 BRAF mutations 69 mL/min/#.# m 2 69 folic acid takers 69 histologic subtype 69 invasive carcinoma 69 stage IIIb IV 69 tumor recurrence 69 LV dysfunction 69 precursor lesions 69 hepatocellular carcinomas 69 endometrial carcinoma 69 extracapsular extension 69 biochemical relapse 69 serous ovarian cancer 69 intestinal polyps 69 CC genotype 69 vertebral fracture 69 EUS FNA 69 obstructive coronary artery 69 KRAS mutations occur 69 thyrotropin levels 69 metachronous 69 metastatic lesions 69 K ras mutations 69 nodal metastasis 69 pT2 69 BRCA2 mutation carriers 69 elevated LDH 69 unresectable tumors 68 precancers 68 beta carotene supplementation 68 definite stent thrombosis 68 lymph node metastasis 68 PSA nadir 68 colorectal liver metastases 68 HbA 1c levels 68 grade cervical intraepithelial 68 node metastases 68 colorectal carcinomas 68 mammographic density 68 axillary node dissection 68 hip BMD 68 glycated hemoglobin levels 68 proximal colon 68 malignant growths 68 GISTs 68 transferrin saturation 68 sentinel nodes 68 leucopenia 68 renal tumors 68 colonic polyps 68 liver metastasis 68 TEAEs 68 MGUS 68 hematologic toxicity 68 benign nodules 68 deep venous thromboses 68 EpCAM expression 68 axillary nodes 68 elevated CRP 68 intestinal metaplasia 68 ALND 68 PCA3 scores 68 colorectal carcinoma 68 KRAS mutations 68 adenoma recurrence 68 benign lesions 68 confidence interval #.#-#.# 68 SHBG levels 68 mucinous 68 resectable 68 extracolonic findings 68 adjuvant radiotherapy 68 atypical ductal hyperplasia 68 nonmetastatic 68 intima media thickness 68 pancreatic adenocarcinoma 68 mammographically 68 MMSE scores 68 postoperative chemotherapy 68 completely resected 68 serum creatinine levels 68 thyroid nodules 67 chlamydial infection 67 radical nephrectomy 67 colon rectal 67 glomerular filtration 67 β blockers 67 hyperplastic polyps 67 postoperative morbidity 67 relapsed MM 67 nonmelanoma skin cancer 67 basal cell carcinoma BCC 67 bowel polyps 67 meningiomas 67 serum calcium levels 67 NMIBC 67 catheter angiography 67 oral antidiabetic medication 67 nodal metastases 67 lobular carcinomas 67 grade dysplasia 67 flutamide 67 distal colon cancer 67 nonvertebral fractures 67 hamartomas 67 tumor histology 67 lymphadenectomy 67 cervical intraepithelial neoplasia 67 Radical prostatectomy 67 ADPKD 67 binary restenosis 67 B7 H3 67 troponin T 67 gastric adenocarcinoma 67 baseline LDH 67 neoadjuvant chemotherapy 67 gallstone disease 67 situ LCIS 67 urine cytology 67 microbleeds 67 basal cell carcinomas 67 neurologic complications 67 asymptomatic carotid stenosis 67 HER2 amplification 67 malignant nodules 67 colorectal tumors 67 neoadjuvant therapy 67 tibolone 67 contralateral breast cancer 67 poor metabolizers 67 HBeAg negative 67 stent stenosis 67 TNF blocker therapy 67 mycophenolate mofetil 67 prostate carcinoma 67 thromboembolic events 67 complete cytogenetic response 67 ASCUS 67 rebleeding 67 Postoperative complications 67 hemoglobin A1c levels 67 underwent coronary angiography 67 curative resection 67 paricalcitol 67 Adjuvant chemotherapy 67 Squamous 67 GnRH agonists 67 T2 lesions 66 atypia 66 metastatic prostate 66 bowel cancers 66 axillary dissection 66 revascularization procedures 66 lymphovascular invasion 66 ALT elevation 66 histologically confirmed 66 FluCAM arm 66 transrectal ultrasound guided 66 pre cancerous growths 66 severe periodontitis 66 thyroglobulin 66 Hurthle cell 66 progesterone receptor negative 66 postoperative mortality 66 perioperative mortality 66 upper gastrointestinal bleeding 66 systolic dysfunction 66 radioiodine therapy 66 carotid IMT 66 histological subtype 66 hemorrhagic complications 66 leiomyomas 66 postoperative complication 66 polypoid lesions 66 hematopoietic cancers 66 breast endometrial 66 breast carcinoma 66 CrCl 66 FOLFOX4 66 lobular breast cancer 66 lipid lowering medications 66 liver metastases 66 precancerous cervical 66 grade gliomas 66 Papillary 66 bezafibrate 66 peritoneal cancer 66 undergoing radical prostatectomy 66 ARB telmisartan 66 ximelagatran 66 arterial thromboembolic events 66 cervical lesions 66 underwent radical prostatectomy 66 hydroxyvitamin D levels 66 Colon polyps 66 thromboembolism 66 bilateral oophorectomy 66 neutrophil counts 66 epithelial ovarian cancer 66 coronary stenosis 66 pancreatic lung 66 Hb A1C 66 NNRTI resistance 66 seminomas 66 elevated ALT 66 urothelial carcinoma 66 metastases 66 PASI scores 66 endometriosis ovarian cysts 66 prolonged QT interval 66 androgen deprivation 66 hypophosphatemia 66 esophageal cancers 66 BRCA2 mutations 66 μmol L 66 nondiabetics 66 poorer prognosis 66 patients undergoing CABG 66 ertapenem 66 revascularizations 66 angiographic restenosis 66 skeletal metastases 66 pretest probability 66 GSTP1 66 preoperative PSA 66 placebo dexamethasone 66 calcified plaques 66 elevated troponin 66 lactate dehydrogenase 66 hepatic metastases 66 testicular tumors 66 endometrial ovarian 66 MetS 66 HER2 overexpression 66 bladder tumors 66 aminotransferases 66 nonfasting triglyceride levels 66 intravesical therapy 66 alanine aminotransferase ALT 66 NP CRNs 66 lowest tertile 66 conventional angiography 66 lung lesions 66 % CI #.#-#.# [003] 65 dutasteride 65 metastatic RCC 65 clinically detectable 65 Ishak fibrosis score 65 creatinine ratio 65 nonvertebral fracture 65 prostate TURP 65 tamoxifen Nolvadex ® 65 axillary node 65 CsA 65 breast carcinomas 65 upper endoscopy 65 prednisone prednisolone 65 anal cancers 65 lymphocytosis 65 dysplastic nevi 65 locoregional 65 univariate analysis 65 pancreatic prostate 65 corticosteroid therapy 65 undetectable HBV DNA 65 endometrial thickness 65 micrometastasis 65 elevated serum creatinine 65 oxycodone CR 65 Hazard Ratio HR 65 HBeAg 65 adjuvant radiation 65 baseline HbA1c 65 EGFR mutations 65 situ CIS 65 total thyroidectomy 65 CVD mortality 65 octreotide LAR 65 FDG uptake 65 Rectal cancer 65 adnexal mass 65 lymph node removal 65 subependymal giant cell 65 dalteparin 65 cytoreductive surgery 65 mutated K ras 65 ejection fractions 65 clinically localized prostate 65 obstructive CAD 65 lung metastases 65 mesotheliomas 65 neuroblastoma tumors 65 radical prostatectomy RP 65 lopinavir r arm 65 serum calcium 65 KRAS mutation 65 leukopenia 65 % CI #.#-#.# [007] 65 androgen suppression 65 cardiac troponin T 65 pre cancerous lesions 65 cerebral microbleeds 65 recurrent venous thromboembolism 65 serum urate levels 65 recurrent glioblastoma multiforme 65 sirolimus stent 65 carotid plaque 65 grade squamous intraepithelial 65 HBeAg seroconversion 65 ischemic lesions 65 prostate abnormalities 65 microscopic hematuria 65 basal cell skin 65 HER2 negative 65 microalbuminuria 65 recurrent DVT 65 pg ml 65 ovarian carcinoma 65 alanine aminotransferase 65 renal toxicity 65 BMD measurements 65 GSTM1 65 cytogenic 65 BRAF mutation 65 reinfarction 65 paclitaxel eluting stents 65 elevated triglyceride levels 65 postoperative infections 65 polyp detection 65 extrapyramidal symptoms 65 IV bisphosphonates 65 invasive coronary angiography 65 non squamous NSCLC 65 thoracoscopic lobectomy 65 #ng/ml 65 atheroma volume 65 malignant neoplasm 65 melanoma lesions 65 lung nodule 65 postintervention 65 neoplasm 65 distal colon 65 nondiabetic 65 lumbar spine BMD 65 serum uric acid 65 metastatic colorectal 65 beta blocker therapy 65 NNT = 65 intracranial hemorrhage ICH 65 INCB# [003] 65 ductal lobular 65 carotid plaques 65 non aspirin NSAIDs 65 ovarian endometrial 65 metastatic lymph nodes 65 recurrent metastatic 65 scintigraphic 65 nonobese 65 premalignant lesions 65 CLA supplementation 65 Subgroup analyzes 65 TMP SMX 65 breast lesions 65 dietary folate intake 65 fasting glucose levels 65 atherosclerotic lesions 65 multivariable analysis 65 varices 65 albumin excretion rate 65 platelet reactivity 65 atypical lobular hyperplasia 65 lung metastasis 65 fluvastatin 65 oesophageal adenocarcinoma 65 ovarian pancreatic 65 achieved ACR# 65 umol L 65 postoperative complications 65 noncardiac 65 basal cell cancers 65 fibroadenomas 65 MACCE 65 squamous cell cancers 65 stratifying patients 65 diabetes mellitus DM 65 untreated celiac disease 65 HIV HCV coinfected 64 KRAS mutant tumors 64 ritonavir boosted 64 CYPHER Stent 64 macroalbuminuria 64 T1c 64 colorectum 64 osteopenic 64 peritoneal carcinomatosis 64 precancerous lesions 64 nonischemic 64 invasive lobular carcinoma 64 Platinol ® cisplatin 64 hemoglobin A1c HbA1c 64 serum homocysteine 64 carotid artery blockage 64 invasive ductal breast cancer 64 histopathologic examination 64 intact parathyroid hormone 64 haematologic 64 ABCB1 64 TAXUS Express Stent 64 oophorectomy 64 parous women 64 squamous cell lung cancer 64 HbA1C 64 moderate renal impairment 64 morphometric vertebral fractures 64 epithelial ovarian 64 mIU ml 64 leukocyte count 64 NSTE ACS 64 transaminase levels 64 benign polyps 64 CaP 64 sonographically 64 tPSA 64 nonfatal MI 64 5-FU/LV 64 subclinical hypothyroidism 64 nonalcoholic steatohepatitis NASH 64 TNF antagonist 64 neoplasms 64 Kaplan Meier analysis 64 cystatin C 64 CCyR 64 sentinel lymph node biopsy 64 colorectal cancer CRC 64 lipid lowering agents 64 triglyceride concentrations 64 BRCA mutations 64 GBA mutations 64 receiving VELCADE 64 premenopausal breast cancer 64 intraoperative complications 64 liver transplant recipients 64 hepatorenal syndrome 64 HbA1C levels 64 lactate dehydrogenase LDH 64 venous blood clots 64 wedge resection 64 PREZISTA r arm 64 coronary blockages 64 histologically proven 64 gadolinium enhanced 64 APTIVUS r 64 nicardipine 64 untreated metastatic melanoma 64 sarcosine 64 A1c levels 64 HbA 1c 64 radiotherapy RT 64 HbA1c levels 64 noncancer 64 proliferative diabetic retinopathy 64 precancer 64 clinically insignificant 64 anthracycline taxane 64 cell carcinomas 64 #Gy 64 Folfox 64 Doxil ® 64 metastatic pancreatic 64 hyperplastic 64 #mmHg [001] 64 Aspergillus infections 64 caspofungin 64 GSTT1 64 polypoid 64 Thal Dex 64 antihypertensive medications 64 malignant melanomas 64 sarcomatoid 64 hsCRP levels 64 alemtuzumab treated 64 dysglycemia 64 comparator arm 64 cervical carcinoma 64 highest tertile 64 metastatic gastric 64 Hematologic 64 S. aureus isolates 64 asymptomatic PAD 64 XIENCE V PROMUS Stent 64 ALA PDT 64 papillary renal cell carcinoma 64 metastatic lung cancer 64 obese postmenopausal 64 urate levels 64 highest quintile 64 BRCA mutation carriers 64 urothelial cancer 64 guaiac 64 clodronate 64 colon polyps 64 lipid abnormalities 64 serum concentrations 64 malignant prostate 64 laboratory abnormalities 64 perioperative complications 64 REYATAZ r arm 64 malignant lymph nodes 64 hydroxychloroquine 64 histologically 64 sulphonylureas 64 precancerous tumors 64 HBeAg negative patients 64 mIU L 64 symptomatic intracerebral hemorrhage 64 squamous 64 microalbumin test 64 chronic periodontitis 64 recurrent NSCLC 64 Erythropoietic therapies may 64 BCR ABL mutations 64 T2 lesion volume 64 VTEs 64 transaminase elevations 64 Cervista HPV HR 64 perioperatively 64 neoplasia 64 occult metastases 64 cranial irradiation 64 vertebral fractures 64 colon tumors 64 stage IIIB 64 BRCA mutation 64 pulmonary dysfunction 64 amoxicillin clavulanate 64 seminal vesicle invasion 64 squamous histology 64 BRAF V#E 64 curable cancers 64 serum urate 64 para aortic 64 low dose Iluvien 64 elevated LDL cholesterol 64 conventional coronary angiography 64 stage IIIA 64 pneumonectomy 64 serum phosphate 64 severe exacerbations 64 taxane therapy 64 Complication rates 64 pathologic diagnosis 64 hepatic enzymes 64 squamous cell histology 64 Basal cell 64 serum lipid levels 64 testicular cancers 64 nonsmall cell lung cancer 64 antibody titer 64 cTnI 64 serum selenium 64 fasting triglyceride levels 64 pamidronate 64 QTc prolongation 64 postoperative infection 64 oropharyngeal cancer 64 carotid artery thickness 64 premalignant 64 paroxysmal AF 64 papillary carcinoma 64 seminoma 64 sulfasalazine 64 shorter telomere length 64 subtrochanteric 64 STRIDE PD 64 CLL SLL 64 CMV infection 64 mg BID dose 64 serum prostate 64 Baseline characteristics 64 serum aminotransferase levels 63 ErbB2 positive 63 gross hematuria 63 rheumatoid factor 63 gastric cancers 63 fasting insulin 63 myocardial infarctions 63 cTnT 63 candidemia 63 lipid lowering drugs 63 Hazard Ratio 63 CIMZIA ™ 63 nmol L 63 prostate adenocarcinoma 63 HPV-#/# 63 precancerous cervical lesions 63 thyroid carcinoma 63 QTcF 63 DEXA scans 63 coronary artery calcification 63 HER2 amplified 63 rs# [002] 63 pheochromocytoma 63 excisional biopsy 63 CP CPPS 63 breast pancreatic 63 cholelithiasis 63 benazepril 63 bone scintigraphy 63 frequently benign tumor 63 premalignant lesion 63 mineral density 63 idiopathic PAH 63 severe neutropenia 63 IFN beta 63 F FDG PET 63 debulking surgery 63 undergoing coronary angiography 63 infarcts 63 albumin excretion 63 oral squamous cell 63 perimenopausal women 63 CYT# potent vascular disrupting 63 undergo prostate biopsy 63 venous thrombosis 63 sentinel lymph nodes 63 plasma homocysteine levels 63 varicoceles 63 overt nephropathy 63 mcg QD 63 esophageal squamous cell carcinoma 63 epithelioid 63 preoperatively 63 prognostic variables 63 anti JCV antibodies 63 diverticular bleeding 63 metastatic GIST 63 castrate resistant 63 mutated KRAS 63 Plasma concentrations 63 pericardial effusion 63 BRAF V#E mutation 63 coinfected 63 Basal Cell 63 indinavir 63 HNPCC 63 elevated IOP 63 receiving prophylactic anticoagulation 63 nonproliferative 63 GBM tumors 63 intraobserver 63 XELOX 63 confidence intervals CIs 63 CIN2 63 uveal melanoma 63 Flu Cy 63 antiandrogen 63 HCV antibody 63 transaminases 63 KRAS status 63 carcinomas 63 cutaneous melanoma 63 tertile 63 DFMO 63 microvascular complications 63 gestational diabetes mellitus 63 corticosteroid dose 63 Avandia Actos 63 microbiological eradication 63 ovarian breast 63 Asymptomatic 63 genotypic resistance 63 arterial occlusion 63 ALT flares 63 glioma tumors 63 femoral neck fracture 63 malignant pleural mesothelioma 63 nephrotoxicity 63 follicular lymphomas 63 benign noncancerous 63 hyperplasia BPH 63 hormone therapy estrogen 63 idraparinux 63 gastric cardia 63 rs# [004] 63 SGPT 63 fewer uterine cancers 63 chemoembolization 63 P = .# 63 CTAP# Capsules 63 cilostazol 63 gadobutrol 63 hypervascular tumors 63 oncologic outcomes 63 achieved CCyR 63 NAFLD 63 squamous cell carcinoma SCC 63 neoadjuvant 63 T2DM 63 esophageal gastric 63 recurrent UTI 63 RAS mutations 63 latent celiac disease 63 neoplastic lesions 63 metaplasia 63 ibandronate 63 hypermethylated 63 precancerous condition 63 atrophic gastritis 63 renal cysts 63 fallopian tube carcinoma 63 Breslow thickness 63 NAbs 63 CR nPR 63 protein excretion 63 femoral neck BMD 63 metastatic bladder 63 intensive statin therapy 63 p# biomarker 63 BRCA2 carriers 63 tanned indoors 63 CI #.#-#.# [002] 63 low expressors 63 rectal cancers 63 hyperphenylalaninemia HPA due 63 alkaline phosphatase ALP 63 sCJD 63 nonpregnant women 63 perioperative morbidity 63 serum phosphorous 63 biopsy Gleason 63 cTnT levels 63 seroconverted 63 percutaneous biopsy 63 EGFR mutation 63 lobular 63 lung carcinomas 63 tHcy 63 urine albumin 63 squamous cell 63 IFN alfa 63 baseline FEV 63 POAG 63 stenoses 63 dose ionizing radiation 63 chemoradiation therapy 63 variceal hemorrhage 63 tamsulosin 63 IDH1 mutation 63 GP IIb IIIa inhibitors 63 liver biopsies 63 artery stenosis 63 glycosylated hemoglobin HbA1c 63 grade glioma 63 oral antidiabetes 63 axillary lymph node dissection 63 Digital Mammographic Imaging 63 pentoxifylline 63 thiazide diuretics 63 cytologic 63 ocular toxicity 63 mU liter 63 undetectable PSA 63 coinfected patients 63 isoprostane 63 carcinoids 63 adrenocortical cancer 63 serum ALT 63 thromboembolisms 63 cisplatin resistant 63 multivariate analyzes 63 sirolimus eluting stents 63 colorectal bowel 63 fibrate drugs 63 serum IgE 63 nanomolar 63 Taxus Stent 63 NATRECOR R 63 fetuin 63 cutaneous squamous cell carcinoma 63 BRCA2 mutation 63 metastatic malignant 63 titrated glipizide 63 axillary lymph node 63 NATRECOR ® 63 IL#B 63 receiving VICTRELIS 63 invasive ductal carcinoma 63 prospectively defined 63 pituitary adenomas 63 #mmHg [002] 63 antigen PSA 63 multivariable adjusted 63 preoperative radiotherapy 63 Helicobacter pylori infection 63 endometrioid 63 anastrazole 63 benign growths 63 myelodysplastic myeloproliferative diseases 63 clinically evaluable patients 63 statin monotherapy 63 dapagliflozin plus 63 CK MB 63 spiral computed tomography 63 lobular involution 63 noncalcified 63 intraductal 63 LDL particle 63 infliximab monotherapy 63 N telopeptide 63 pg mL 63 adenocarcinoma 63 esophageal tumors 63 Stent thrombosis 63 IgA deficiency 63 x ULN 63 thrombotic events 63 bovine thrombin 63 CK # plasma concentrations 63 densest breasts 63 cerebrovascular events 63 transurethral resection 63 NMP# 63 optical colonoscopy 63 cytologically confirmed 63 varicocele 63 serum IGF 63 #F FDG 63 prostate pancreatic 63 #mg dose [002] 63 RET PTC rearrangements 63 ipsilateral breast 63 tumoral 63 microvascular disease 63 Renal Cell Carcinoma RCC 63 pelvic lymphadenectomy 63 IOP lowering 63 nonsignificant difference 63 aspirin clopidogrel 63 DCIS lesions 63 mg/m2 dose 63 hematologic abnormalities 63 ruptured aneurysms 62 sUA 62 TP# mutations 62 HOMA IR 62 coronary artery stenosis 62 graft occlusion 62 ß blockers 62 solar keratosis 62 abnormal mammograms 62 neutropaenia 62 #F FDG PET 62 thyroid hormone levels 62 HPV# 62 eosinophil count 62 dexamethasone Decadron 62 micafungin 62 dacarbazine chemotherapy 62 papillary 62 PSA velocity 62 serum testosterone 62 smoldering multiple myeloma 62 adjuvant therapies 62 external genital lesions 62 rosuvastatin #mg 62 chlorambucil 62 endocrine therapies 62 urolithiasis 62 NSCLC tumors 62 chorioamnionitis 62 metastatic neuroendocrine tumors 62 nonmelanoma 62 dysplastic 62 pegylated liposomal doxorubicin 62 chlorthalidone 62 % Confidence Interval 62 uterine cancers 62 atorvastatin #mg 62 LEXIVA r 62 GG genotype 62 MELD scores 62 renal artery stenosis 62 adjunctive placebo 62 papillary thyroid carcinoma 62 Prostate Specific Antigen PSA 62 virologic failure 62 paclitaxel cisplatin 62 MALT lymphoma 62 timepoints 62 BRCA deficient 62 tenecteplase 62 lumbar disk herniation 62 thromboembolic complications 62 adverse reactions incidence 62 salmeterol HFA MDI 62 unresectable HCC 62 Cystatin C 62 selenium intake 62 FDG-PET/CT 62 TTF Therapy 62 onset diabetes mellitus 62 carcinoid tumor 62 certolizumab 62 repigmentation 62 endosonography 62 Candida infection 62 ventricular tachyarrhythmia 62 adenoma detection 62 malignant lymphoma 62 parathyroid 62 underwent CABG